FDA gives the green light for human trials against a new coronavirus therapy
Food and Drug administration approved a new treatment idea against coronavirus for human trials.
Treatment is derived from stem cells in human placentas.
Natural killer cells in the placenta protects a baby from viruses inside the mother while in her womb.
Plans to give infusions of this stem cell therapy to patients in order to get the same protection.
This early stage trial will include up to 86 coronavirus patients with symptoms.
This stem cell therapeutic approach was developed by New Jersey biotech company Celularity.
Mentioned in this article:
Celularity - Cell therapeutics company
FDA - Ensuring safety of drugs, medical supplies and food which is used daily.
Paul Knoepfler - Professor at Department of Cell Biology and Human Anatomy, School of Medicine Genome Center at University of California, Davis
Robert J. Hariri - Surgeon, biomedical scientist and serial entrepreneur in biomedicine and aerospace